Revolution Medicines’ daily targeted pill daraxonrasib extended median survival to 13.2 months versus just 6.7 months with chemotherapy in metastatic patients — a striking advance against one of the deadliest cancers.
🔗
https://www.statnews.com/2026/04/13/revolution-medicines-successful-treatment-pancreatic-cancer-daily-pill/
#Study #HealthNews 🌿
STATRevolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
In a trial, metastatic pancreatic cancer patients on the medicine lived twice as long as those on chemotherapy.
